Agios Pharmaceuticals Shows Improved Relative Strength; Still Shy Of Benchmark [Investor's Business Daily]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Investors Business Daily
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post Agios Pharmaceuticals Shows Improved Relative Strength; Still Shy Of Benchmark appeared first on Investor's Business Daily .
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-ThalassemiaGlobeNewswire
- Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive OfficerGlobeNewswire
- Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q2 2022 Results - Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at SVB Leerink LLC from $33.00 to $37.00. They now have an "outperform" rating on the stock.MarketBeat
- Agios Reports Business Highlights and Second Quarter 2022 Financial ResultsGlobeNewswire
AGIO
Earnings
- 8/4/22 - Beat
AGIO
Sec Filings
- 8/9/22 - Form 3/A
- 8/9/22 - Form 4
- 8/9/22 - Form 3
- AGIO's page on the SEC website